The story we would like to tell about cell and gene therapy (CGT) is straightforward: science is advancing, regulators are modernizing, approvals are rising and patients will benefit. The latest regulatory report we have done in collaboration with the International Society for Cell & Gene Therapy shows that story is only half true. The other half is messier, more consequential, and more urgent.<\/p>\n
Here are three truths that are difficult to ignore. They are grounded in what the clinical trial pipeline, registration approvals, withdrawals, and regulatory activity are actually revealing.<\/p>\n
The pipeline is active: 322 global clinical trials across regions, dominated by Phase I\/II activity. Genetically modified cell therapies account for 53% of trials, with gene therapies building momentum.<\/p>\n
But here is the uncomfortable part: a large pipeline does not automatically translate into a large patient impact. When most activity sits in early phases, it signals not just innovation but also high attrition, long timelines, and repeated reinvention.<\/p>\n
The market is sending signals that the breakthrough-to-blockbuster path is not reliable. The report documents product withdrawals\/cancellations for reasons including limited demand and pricing issues rather than scientific failure.<\/p>\n
This means that CGT is colliding with a reality where manufacturing complexity, comparability, site readiness, and post-approval evidence generation determine success as much as clinical efficacy.<\/p>\n
What to do about it:<\/p>\n
Regulatory agencies are actively reshaping the roadmap to market:<\/p>\n
This looks like progress, but the uncomfortable truth is that accelerated pathways can amplify weak development strategies just as quickly as they accelerate good ones.<\/p>\n
When programs are built around getting through the gate, they often underinvest in:<\/p>\n
The report\u2019s withdrawals and suspensions, including safety-related actions, are a reminder: post-approval is where CGT reputations are made.<\/p>\n
This means that regulators are increasingly willing to be flexible on how you generate evidence, but not on whether you can sustain it across the product lifecycle.<\/p>\n
What to do about it:<\/p>\n
Companies still behave as if the world is sequential: start in the U.S., validate in the E.U., then expand to rest of the world. But the regulatory activity points to a more multipolar reality:<\/p>\n
This creates a strategic discomfort: regulatory influence and development speed are not confined to the traditional hubs, and competitive advantage can emerge from markets many companies still treat as a later strategy.<\/p>\n
This means global strategy is shifting from sequencing to orchestration. Those who can\u2019t operate in a world where requirements evolve in parallel will be outpaced by those who can.<\/p>\n
What to do about it:<\/p>\n
In summary, the next chapter for CGT will demand:<\/p>\n
The CGT sector has enough innovation. What it lacks is the infrastructure of evidence, manufacturing, access, and sustained regulatory alignment required to convert breakthrough biology into routine medical care.<\/p>\n